2622254-57-1
2622254-57-1
Chemical Structure
Bempikibart
Synonym(s): ADX-914
- CAS No.: 2622254-57-1
- Formula:N/A
- Molecular Weight:(145.745 kDa)
SMILES: [Bempikibart]
Biological Activity: Bempikibart (ADX-914) is a fully human IgG1-κ monoclonal antibody targeting IL-7Rα. Bempikibart binds to the IL-7 receptor alpha and blocks IL-7 and TSLP signaling. Bempikibart reduces T cell populations while relatively preserving regulatory T cells. Bempikibart inhibits Th1, Th2, and Th17 immune pathways. Bempikibart can be used in research on alopecia areata and atopic dermatitis[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Bempikibart | 98% | Bempikibart (ADX-914) is a fully human IgG1-κ monoclonal antibody targeting IL-7Rα. Bempikibart binds to the IL-7 receptor alpha and blocks IL-7 and TSLP signaling. Bempikibart reduces T cell populations while relatively preserving regulatory T cells. Bempikibart inhibits Th1, Th2, and Th17 immune pathways. Bempikibart can be used in research on alopecia areata and atopic dermatitis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Ungar B, et al. Alopecia areata. Nature Reviews Disease Primers. 2025 Nov 6;11(1):77.
- [2]. Galand C, et al. 221 Bempikibart, a Novel Human IL-7Rα Antagonist Inhibiting IL-7 and TSLP Signaling, Demonstrated Robust Impact on T-cell Maintenance and Th2 Responses in T-cell Driven Skin Disease. Journal of Investigative Dermatology. 2025 Nov 1;145(11):e65.
